Business Wire

IN-NTT/NTT-DATA

23.5.2024 16:06:30 CEST | Business Wire | Press release

Share
NTT and NTT DATA Roar into the Indianapolis 500 with AI-powered Fan Experience

NTT, a leading global technology and business solutions provider, and NTT DATA continue to expand innovative use of racing data to improve fan experiences across the NTT INDYCAR SERIES, including this year’s Indianapolis 500.

NTT is the parent company of NTT DATA, and they serve together as Official Technology Partner of INDYCAR, the NTT INDYCAR SERIES, Indianapolis Motor Speedway (IMS), the Indianapolis 500, and NASCAR Brickyard weekend.

Through 140-plus sensors on each racecar, NTT DATA captures and analyzes more than 8 billion racing datapoints in the NTT Smart Solutions Platform. Leveraging advanced AI and predictive analytics, the company shares near-real-time insights and visualizations to fans both onsite and remotely for enhanced storytelling of key moments during events including head-to-head overtaking, race strategies, race winner predictions and more. Additionally, the 300,000-plus fans onsite for the race benefit from data on wait times and flow across the 600-plus acre venue calibrated every 30 seconds.

SMART Venues Improve the Fan Experience
Fans at the Indianapolis 500 or other events at the Indianapolis Motor Speedway can experience NTT DATA Smart Venue technology, sustainability solutions and live race data at the Pagoda command displays. For example, AI-enabled optical detection technologies improve security and traffic flow, and when combined with digital ticketing, provide real-time and future prediction wait times at the event gates and concessions. This allows fans at the world’s largest single-day sporting event to move through the venue as safely and efficiently as possible.

AI-enabled Racing Insights
Whether at the racetrack, at home or on the go, fans of the NTT INDYCAR SERIES can also tap into the INDYCAR App Powered by NTT DATA to stay up to date on all of the latest developments. The App allows fans to get even closer to the action with real-time, AI and advanced analytics providing racing insights that include live scoring and viewing of the drivers in action courtesy of 15 in-car cameras. The App, which historically engages more than 70,000 users on race days, is available for download from the iOS App Store and Google Play.
NTT DATA also continues to enable other similar innovative experiences to benefit fans and increase engagement across all mediums, via social media, the web and television or streaming broadcast, through reliable technology and services that deliver deeper data insights.

Race Like the Pros
This year, a new limited racing demonstration will leverage Embodied Knowledge technology from NTT R&D. Embodied Knowledge powers simulators that blend physical sensations with digital innovation, allowing users to precisely experience a track as driven by a professional driver. Beyond the experience of traditional simulators, Embodied Knowledge adds the actual feel and performance of the professional driver at high speeds at the Indianapolis Motor Speedway including realistic steering wheel forces and car behavior like vibrations and forces exerted on seat, users can synchronize their movements with that of a professional driver via XR.

NTT Embodied Knowledge technology is being explored for future use cases including medical surgery training, coaching and fan experiences in sports. Future applications include employee training across retail, education, and manufacturing, as well as enabling AI-robots to learn how to move and react the way humans do to perform tasks from restocking shelves to in-home caregiving. The effort is part of the more than $3.6B NTT invests each year in research and development, uncovering innovations that have commercial impact for their customers.

“The Indianapolis 500 is the pinnacle of racing that leverages refined Embodied Knowledge where firsthand the movements of racers can be felt to understand what Embodied Knowledge truly means. Through various sensing technologies, we aim to technically recreate these movements and sensations.” said Kota Hidaka, Vice President, Head of NTT Human Informatics Laboratories.

To learn more about the NTT INDYCAR SERIES, visit: https://us.nttdata.com/en/about-us/content/ntt-indycar-series.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523988191/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye